Status:
UNKNOWN
Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE
Lead Sponsor:
Assiut University
Conditions:
Systemic Lupus
Eligibility:
All Genders
1+ years
Brief Summary
Systemic lupus erythematosus (SLE) is systemic autoimmune disease characterized by various immunological abnormalities, including dysregulated activation of both T and B lymphocytes with overt product...
Detailed Description
Systemic lupus erythematosus (SLE) is systemic autoimmune disease characterized by various immunological abnormalities, including dysregulated activation of both T and B lymphocytes with overt product...
Eligibility Criteria
Inclusion
- SLE patients diagnosed according to ACR
Exclusion
- patient with other autoimmune diseases.
Key Trial Info
Start Date :
March 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT03752983
Start Date
March 1 2019
End Date
December 1 2020
Last Update
January 29 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.